帕金森氏症治療藥的全球市場 (2022-2028年):各藥物類型 (脫羧酶抑制劑、多巴胺促效劑)、給藥途徑、流通管道的規模、佔有率、成長分析、預測

Global Parkinson's Disease Drug Market Size, Share, Growth Analysis, By Drug Type(Decarboxylase Inhibitors, Dopamine Agonists), By Route of Administration, By Distribution Channel - Industry Forecast 2022-2028

出版日期: 2023年04月13日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

帕金森氏症治療藥的市場規模，2021年是42億8,000萬美元，2022年是46億1,000萬美元，從2023年到2030年的預測期間中預計以12.1％的年複合成長率發展，2030年成長到119億8,000萬美元的規模。

由於疾病盛行率上升，為了管理症狀需要長的期間，預計在預測期間內的市場成長。還有也由於腦移植的並用藥的需求劇增，延長持續刺激多巴胺作動性神經元的藥物的作用，基因治療，政府的資金提供計劃等各種要素而成長。

本報告提供全球帕金森氏症治療藥的市場調查，市場概要，市場的各種影響因素的分析，技術、革新趨勢，市場規模的變化、預測，各種區分、各地區的明細，競爭情形，主要企業簡介等彙整資訊。

市場動態
促進因素
機會
阻礙因素
課題
法規情形
SWOT分析
波特分析
未來阻礙相關Skyquest的特別洞察
全球帕金森氏症治療藥市場:各藥物類型
脫羧酶抑製劑抑制劑(左旋多巴/碳度巴)
多巴胺促效劑
單胺氧化酶B型(MAO-B)抑制劑
兒茶酚-O-甲基轉移酵素(COMT)抑制劑
全球帕金森氏症治療藥市場:各給藥途徑
口服
注射劑
經皮
全球帕金森氏症治療藥市場:各流通管道
醫院藥局
零售藥局
線上藥局

市場規模:各地區

北美
歐洲
亞太地區
南美
中東、非洲

主要企業簡介

競爭情形
對像企業數
主要企業的地位
主要企業的市場佔有率
Pfizer, Inc.
Impax Laboratories, Inc.
Hoffmann-La Roche Ltd
Novartis Ag
Merck &Co., Inc.
Orion Pharma
Teva Pharmaceutical Industries Ltd.
Boehringer Ingelheim GmbH
Acadia Pharmaceuticals Inc.
Vertical Pharmaceuticals, Llc
GlaxoSmithKline PLC
Acadia Pharmaceuticals Inc.
Dr. Reddy's Laboratories Ltd.
Wockhardt
Stada Arzneimittel Ag
Mylan NV
Cipla Inc.
Par Pharmaceutical
Daiichi Sankyo Company Ltd
Apotex Inc.

簡介目錄

Product Code: SQSG35I2024

Global Parkinson's Disease Drug Market size was valued at USD 4.28 billion in 2021 and is poised to grow from USD 4.61 billion in 2022 to USD 11.98 billion by 2030, growing at a CAGR of 12.1% in the forecast period (2023-2030).

Parkinson's disease is a neurological ailment that mostly affects the parts of the brain responsible for controlling movement, making it difficult to perform daily tasks. Parkinson's disease currently affects more than 10 million people worldwide. Tremors, stiffness, difficulty walking, and other symptoms are typically seen because of the decrease in dopamine production that results from it. Over the course of the forecast period, the Parkinson's disease drug market is anticipated to rise due to the rising prevalence of the condition and the lengthy time period needed to manage its symptoms. The market for Parkinson's disease is growing due to a variety of factors, including the surge in demand for combination medicines that promote brain transplantation, the extended effect of medications that constantly stimulate dopaminergic neurons, gene therapy, and government funding programmes.

The Parkinson's disease market is also benefited by the growing population, an improved healthcare system, research and development initiatives, and greater healthcare costs. Due to the patent expiration of branded medications and a strong drug pipeline, the Parkinson's disease market players are also anticipated to profit from profitable prospects for the duration of the projected time.

Top-down and bottom-up approaches were used to estimate and validate the size of global Parkinson's Disease Drug Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Segments covered in this report

The Global Parkinson's Disease Drug Market is segmented based on drug type, route of administration, distribution channel, and region. Based on Drug Type, it is categorized into Decarboxylase Inhibitors (Levodopa/Carbidopa), Dopamine Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitors. Based on Route of Administration, it is categorized into Oral, Injection, and Transdermal. Based on Distribution Channel, it is categorized into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on region, it is categorized into North America, Europe, Asia Pacific, The Middle East and Africa, and Latin America.

Drivers

The ageing of the population and the rise in Parkinson's cases: Two significant factors influencing the growth of this market are the increasing ageing of the population and the incidence of neurological diseases. Parkinson's disease sufferers are becoming more numerous, which is driving up demand for the medications needed to treat the condition. Over the projected period, this is anticipated to boost the expansion of the global market for Parkinson's disease medications.

Restraints

It is anticipated that the market expansion will be constrained by the high cost of treating Parkinson's disease: Due to the high cost of treating Parkinson's disease, which is the primary factor impeding the market's growth throughout the forecast period, the financial burden of Parkinson's disease is growing on people, families, and the national government.

Market Trends

An increase in Parkinson's disease research and development: The increase in funding from governments and businesses for the study and development of Parkinson's disease pharmaceuticals is a significant trend in the market for Parkinson's therapies. Companies engaged in the drug development for this condition are working to create novel and cutting-edge treatments for the condition. As a result, growing investments in the creation of Parkinson's pharmaceuticals are anticipated to sustain the market for medications treating the condition.

Executive Summary

Market overview

Exhibit: Executive Summary - Chart on Market Overview
Exhibit: Executive Summary - Data Table on Market Overview
Exhibit: Executive Summary - Chart on Global Global Parkinson's Disease Drug Market Characteristics
Exhibit: Executive Summary - Chart on Market by Geography
Exhibit: Executive Summary - Chart on Market Segmentation
Exhibit: Executive Summary - Chart on Incremental Growth
Exhibit: Executive Summary - Data Table on Incremental Growth
Exhibit: Executive Summary - Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

Market Dynamics
Exhibit: Impact analysis of DROC, 2021
Drivers
Opportunities
Restraints
Challenges
SWOT Analysis

KEY MARKET INSIGHTS

Technology Analysis
(Exhibit: Data Table: Name of technology and details)
Pricing Analysis
(Exhibit: Data Table: Name of technology and pricing details)
Supply Chain Analysis
(Exhibit: Detailed Supply Chain Presentation)
Value Chain Analysis
(Exhibit: Detailed Value Chain Presentation)
Ecosystem Of the Market
Exhibit: Parent Market Ecosystem Market Analysis
Exhibit: Market Characteristics of Parent Market
IP Analysis
(Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
Trade Analysis
(Exhibit: Data Table: Import and Export data details)
Startup Analysis
(Exhibit: Data Table: Emerging startups details)
Raw Material Analysis
(Exhibit: Data Table: Mapping of key raw materials)
Innovation Matrix
(Exhibit: Positioning Matrix: Mapping of new and existing technologies)
Pipeline product Analysis
(Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
Macroeconomic Indicators

COVID IMPACT

Introduction
Impact On Economy-scenario Assessment
Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
Revised Market Size
Exhibit: Data Table on Global Global Parkinson's Disease Drug Market size and forecast 2021-2027 ($ million)
Impact Of COVID On Key Segments
Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
COVID Strategies By Company
Exhibit: Analysis on key strategies adopted by companies